Hims & Hers Health (NYSE:HIMS) Price Target Cut to $13.25 by Analysts at Citigroup

Hims & Hers Health (NYSE:HIMS) had its target price cut by Citigroup from $16.50 to $13.25 in a report released on Tuesday morning,Benzinga reports. They currently have a sell rating on the stock.

Several other analysts also recently commented on HIMS. UBS Group set a $32.00 target price on shares of Hims & Hers Health in a report on Tuesday, November 4th. Deutsche Bank Aktiengesellschaft set a $31.00 price objective on shares of Hims & Hers Health and gave the stock a “hold” rating in a research report on Tuesday, February 10th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Evercore set a $24.00 target price on shares of Hims & Hers Health in a research report on Tuesday. Finally, Wall Street Zen lowered Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Two investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Reduce” and an average target price of $32.27.

Hims & Hers Health Stock Down 0.5%

HIMS stock opened at $15.43 on Tuesday. The firm has a market capitalization of $3.51 billion, a PE ratio of 30.26, a P/E/G ratio of 2.90 and a beta of 2.43. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $70.43. The stock’s 50 day moving average is $27.79 and its 200-day moving average is $39.76.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.06. The business had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. Hims & Hers Health had a return on equity of 22.25% and a net margin of 5.47%.Hims & Hers Health’s revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.11 earnings per share. Sell-side analysts expect that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Hims & Hers Health announced that its board has initiated a share repurchase program on Monday, November 17th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the company to reacquire up to 3% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Insider Transactions at Hims & Hers Health

In related news, insider Deborah M. Autor sold 7,054 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $258,952.34. Following the sale, the insider owned 6,175 shares of the company’s stock, valued at approximately $226,684.25. The trade was a 53.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Michael Chi sold 13,750 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $504,762.50. Following the completion of the transaction, the chief operating officer owned 305,161 shares in the company, valued at approximately $11,202,460.31. The trade was a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 82,963 shares of company stock valued at $2,944,621. Corporate insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently made changes to their positions in HIMS. Farallon Capital Management LLC grew its stake in shares of Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after acquiring an additional 2,533,271 shares during the period. Invesco Ltd. raised its stake in Hims & Hers Health by 502.2% in the 2nd quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock valued at $127,237,000 after acquiring an additional 2,128,587 shares during the period. Norges Bank purchased a new stake in Hims & Hers Health during the fourth quarter valued at about $62,153,000. Clear Street LLC bought a new position in Hims & Hers Health during the second quarter worth about $83,582,000. Finally, Clear Street Group Inc. bought a new position in Hims & Hers Health during the third quarter worth about $87,372,000. 63.52% of the stock is currently owned by institutional investors.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Beat on EPS and subscriber growth — HIMS reported Q4 revenue up ~28% YoY and an EPS beat while saying subscribers have crossed 2.5 million, showing demand resilience. Hims & Hers Health Reports Mixed Q4 Earnings, Subscribers Cross 2.5 Million
• Positive Sentiment: Acquisition and 2026 revenue guidance provide upside potential — Management projects 2026 revenue of $2.7–$2.9B (above some estimates) and highlighted the Eucalyptus acquisition as an incremental revenue driver. Hims & Hers forecasts 2026 revenue above estimates
• Positive Sentiment: Bullish analyst/features note long‑term growth path — Bullish writeups highlight multi‑year international expansion, Eucalyptus’ contribution and a path to much larger revenue/EBITDA over time. Hims & Hers Health: Don’t Get Lost In The Weeds
• Neutral Sentiment: Unusual options activity — Heavy call buying was reported, which can indicate speculative bullish interest but is not definitive on fundamentals.
• Negative Sentiment: Soft near‑term guidance and margin pressure — Q1 revenue guidance came in below street estimates and margins showed contraction, prompting investor concern about short‑term growth and profitability. Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract
• Negative Sentiment: Regulatory and SEC scrutiny — The company disclosed an SEC probe and management addressed scrutiny over compounding of GLP‑1 products, raising legal and operational risk for its core weight‑loss business. Hims & Hers Health discloses SEC investigation over copycat GLP-1s; stock falls
• Negative Sentiment: Analyst downgrades and price‑target cuts — Several firms trimmed forecasts and ratings (Citigroup cut its target to $13.25 with a sell), increasing near‑term sell pressure. Analyst price target and rating actions

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.